Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics,...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of AGY.L is 13 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell